Michel Aubanel | Molecular Mechanisms Signaling | Research Excellence Award

Published on by Cell Biologist

Mr. Michel Aubanel | Molecular Mechanisms Signaling | Research Excellence Award

Kerry | France

Michel Aubanel is a senior R&D and innovation leader with more than three decades of experience in the flavors, ingredients, and aroma chemicals industry. He has held global leadership roles across major multinational organizations, driving process development, natural extract innovation, flavor optimization, and analytical research. His expertise spans natural and nature-identical molecules, botanical extracts, taste technologies, and advanced flavor delivery systems, with strong involvement in intellectual property creation and patent development. He has led multidisciplinary teams across Europe and the United States and supported global technology deployment across Asia, Africa, and emerging markets, particularly for alcoholic beverages. A recognized contributor to the scientific community, he serves on international science and flavor boards and is an active member of multiple professional chemical societies. His work is reflected in peer-reviewed toxicological publications and granted patents, highlighting a strong commitment to safety, innovation, and sustainable flavor solutions.

Citation Metrics (Scopus)

100
75
50
25
10
0

Citations
59

Documents
7

h-index
3

Citations

Documents

h-index

Featured Publication

Francesca Santilli | Signal Transduction Mechanisms | Research Excellence Award

Published on by Cell Biologist

Prof. Francesca Santilli | Signal Transduction Mechanisms | Research Excellence Award

Department of Medicine and Aging Science, University of Chieti-Pescara “G. d’Annunzio”Chieti | Italy

Francesca Santilli, MD, PhD, is a leading physician-scientist whose work has substantially advanced the understanding of platelet biology, thrombo-inflammation, and cardio-metabolic disease. Her research focuses on mechanisms of platelet activation, interindividual variability in response to low-dose aspirin, and the interplay between inflammation, oxidative stress, and metabolic dysfunction. She has led major national and international projects, including studies on oxidative stress regulation in aspirin-treated diabetes, peripheral blood megakaryocyte maturation, and the effects of JAK inhibitors on thrombopoiesis in inflammatory disease. Her work has also contributed key insights into biomarkers—such as proteomic signatures, microRNAs, and extracellular vesicles—for cardiovascular and metabolic risk stratification. Additional research explores megakaryocyte biology, accelerated platelet turnover, and the impact of emerging therapies including GLP-1 receptor agonists, SGLT2 inhibitors, and PCSK9 inhibitors. Through extensive collaborations across molecular medicine, proteomics, rheumatology, cardiology, and infectious diseases, she has established interdisciplinary frameworks linking platelet function to diabetes, obesity, MASLD, and vascular disease. With over 160 high-impact publications and leadership roles in several scientific networks, her research continues to inform clinical translation and therapeutic optimization in thrombosis, hemostasis, and metabolic disorders.

Profiles: Google Scholar | Scopus

Featured Publications: 

antilli, F., Vazzana, N., Liani, R., Guagnano, M. T., & Davì, G. (2012). Platelet activation in obesity and metabolic syndrome. Obesity Reviews, 13(1), 27–42.

Santilli, F., Rocca, B., De Cristofaro, R., Lattanzio, S., Pietrangelo, L., Habib, A., & Patrono, C. (2009). Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin “resistance.” Journal of the American College of Cardiology, 53(8), 667–677.

Rocca, B., Santilli, F., Pitocco, D., Mucci, L., Petrucci, G., Vitacolonna, E., … & Patrono, C. (2012). The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 10(7), 1220–1230.

Caricato, A., Conti, G., Della Corte, F., Mancino, A., Santilli, F., Sandroni, C., … & Antonelli, M. (2005). Effects of PEEP on the intracranial system of patients with head injury and subarachnoid hemorrhage: The role of respiratory system compliance. Journal of Trauma and Acute Care Surgery, 58(3), 571–576.

Santilli, F., Vazzana, N., Bucciarelli, L. G., & Davì, G. (2009). Soluble forms of RAGE in human diseases: Clinical and therapeutical implications. Current Medicinal Chemistry, 16(8), 940–952.

Di Castelnuovo, A., Bonaccio, M., Costanzo, S., Gialluisi, A., Antinori, A., … Santilli, F., … & Iacoviello, L. (2020). Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: Survival analysis and machine learning-based findings from the multicentre Italian study. Nutrition, Metabolism and Cardiovascular Diseases, 30(11), 1899–1913.

Vazzana, N., Santilli, F., Cuccurullo, C., & Davì, G. (2009). Soluble RAGE in internal medicine. Internal and Emergency Medicine, 4(5), 389–401.

Davì, G., Santilli, F., & Patrono, C. (2010). Nutraceuticals in diabetes and metabolic syndrome. Cardiovascular Therapeutics, 28(4), 216–226.

Chiarelli, F., Santilli, F., & Mohn, A. (2000). Role of growth factors in the development of diabetic complications. Hormone Research in Paediatrics, 53(2), 53–67.

Davì, G., Chiarelli, F., Santilli, F., Pomilio, M., Vigneri, S., Falco, A., … & Basili, S. (2003). Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration. Circulation, 107(25), 3199–3203.

Manigrasso, M. R., Ferroni, P., Santilli, F., Taraborelli, T., Guagnano, M. T., … & Davì, G. (2005). Association between circulating adiponectin and interleukin-10 levels in android obesity: Effects of weight loss. The Journal of Clinical Endocrinology & Metabolism, 90(10), 5876–5879.

Junning Ma | Cell Surface Receptors | Best Research Article Award

Published on by Cell Biologist

Dr. Junning Ma | Cell Surface Receptors | Best Research Article Award

Zhejiang University | China

Dr. Junning Ma has developed a multidisciplinary portfolio spanning neurosurgery, neural engineering, biomaterials, and nanomedicine. Their work integrates neural stem cell biology, targeted drug delivery, and tumor microenvironment modulation to create innovative therapeutic strategies for brain diseases. They have conducted advanced postdoctoral and doctoral research at major institutions, contributing to National Natural Science Foundation of China (NSFC) Youth Fund projects and multiple US-funded NIH and AHA grants. Their research focuses on biomimetic nanocarriers, including cell membrane-coated nanoparticles, PLGA-based delivery systems, and fusion-membrane technologies designed for precision therapy of glioma, pituitary adenoma, and ischemic stroke.

Key projects include engineered neural stem cell membrane-coated nanoparticles for stroke targeting, biomimetic nanoplatforms for cancer immunotherapy, and tumor microenvironment–responsive delivery systems. They have also contributed to studies on neuromodulation, neurotrophic factor-based therapy, neural stem cell transplantation, and photothrombotic stroke models. Their publication record includes high-impact journals such as Materials Today Bio, Biomaterials, Nano Letters, Small, and Cell Reports Physical Science, covering topics like vascular-targeting nanoclusters, polyphenol nanoparticles, and membrane-engineered carriers.

Overall, their research advances translational nanomedicine and regenerative neuroscience, with an emphasis on targeted therapies capable of overcoming the challenges of brain tumor heterogeneity, the blood–brain barrier, and ischemic neural injury.

Profiles: Scopus | Orcid

Featured Publications: 

Ma, J., Win, Y., Xiaojian, Z., et al. (2023). Enhanced EPR effects by folliculostellate cell membrane–coated nanoparticles on invasive pituitary adenoma. Materials Today Bio.

Ma, J., Dai, L., Jianbo, Y., et al. (2023). Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology. Biomaterials.

Ma, J., Liu, F., Wendy, C., et al. (2020). Co-presentation of tumor antigens with costimulation via biomimetic nanoparticles for effective cancer immunotherapy. Nano Letters.

Ma, J., Zhang, S., Jun, L., et al. (2019). Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membranes of engineered neural stem cells. Small.

Mohamed Dammak | Cell Structure Analysis | Best Academic Researcher Award

Published on by Cell Biologist

Prof. Dr. Mohamed Dammak | Cell Structure Analysis | Best Academic Researcher Award

Faculty of Sciences of Sfax | Tunisia

Professor Mohamed Dammak is a distinguished researcher in the field of chemistry, recognized for his significant contributions to materials science, solid-state chemistry, and nanomaterials. His research primarily focuses on the synthesis, structural characterization, and optical properties of functional materials, including luminescent phosphors, glass ceramics, and doped oxide systems. He has extensively investigated rare-earth-doped materials for photonic and optoelectronic applications, contributing valuable insights into energy transfer mechanisms and material stability under various conditions. Professor Dammak’s scholarly output includes numerous publications in high-impact journals indexed in SCI and Scopus, reflecting his consistent pursuit of scientific excellence. With over 1,100 citations and an h-index of 17, his work has had a measurable influence on contemporary research in materials chemistry. He has also participated in national and international research collaborations, enhancing cross-disciplinary approaches to the development of advanced materials with optical and structural functionalities. Through his academic leadership and commitment to innovation, Professor Dammak continues to advance the understanding and application of inorganic and functional materials, bridging the gap between fundamental research and technological development in the field of chemistry.

Profile: Scopus

Featured Publications:

Dammak, M.*, Abdelmoula, N., Cheikhrouhou-Koubaa, W., & Cheikhrouhou, A. (2021). Short-range magnetic behavior in manganites La₀.₉₃K₀.₀₇Mn₁₋ₓCuₓO₃ (0.0 ≤ x ≤ 0.09) above the Curie temperature. Journal of Physics D: Applied Physics, 54(32), 325002. https://doi.org/10.1088/1361-6463/ac015c

 

Shahab Uddin | Microbiology | Best Researcher Award

Published on by Cell Biologist

Mr. Shahab Uddin | Microbiology | Best Researcher Award

Mr. Shahab Uddin | Department of Life Sciences, Lanzhou University | China

Shahab Uddin, is a dedicated and accomplished microbiologist with a strong background in microbial ecology, molecular biology, and nanotechnology. He is currently pursuing a Ph.D. in Microbiology at Lanzhou University, China, where he is engaged in cutting-edge research involving antibiotic-conjugated magnetic nanoparticles for periodontitis diagnosis. With numerous international publications in high-impact journals and experience across microbiology, mechanobiology, and neuroinflammation research, Shahab is recognized for his exceptional technical skills and scientific contributions. His career has spanned various research institutions, including Sungkyunkwan University in South Korea, where he conducted pivotal studies on nanoparticles and microbial pathogens. Driven by scientific curiosity and a collaborative spirit, Shahab continues to contribute to advancements in microbial and biomedical research. Fluent in English, Urdu, and proficient in scientific communication, he is an ideal candidate for the Best Researcher Award, representing both innovation and perseverance in the life sciences.

Publication Profiles: 

Google Scholar
Orcid

Education:

Shahab Uddin began his academic journey in Pakistan, completing his M.Phil. in Microbiology from Quaid-I-Azam University, Islamabad. During his postgraduate studies, he specialized in microbial ecology and environmental microbiology. His thesis work laid the foundation for his deeper interest in microbial mechanisms and genetic interactions. He further advanced his academic credentials by enrolling in the Ph.D. Microbiology program at Lanzhou University, China. His doctoral research focuses on the application of nanotechnology in microbial diagnostics, specifically using magnetic nanoparticles for periodontal disease detection. Over the years, he has enhanced his technical skills in qPCR, molecular cloning, bioaerosol sampling, and nanoparticle synthesis. His education has been enriched by international collaborations and interdisciplinary exposure, especially in mechanobiology and neuroinflammation. Shahab’s education reflects a blend of foundational microbiology and cutting-edge biomedical research, enabling him to tackle complex scientific challenges with innovation and precision.

Experience:

Shahab Uddin has worked as a Research Assistant at Lanzhou University, actively contributing to a nanotechnology-driven project aimed at improving periodontitis diagnostics through magnetic nanoparticle conjugation. His work bridges microbiology, nanotechnology, and diagnostics, showcasing his interdisciplinary expertise. He has also conducted research under Prof. Sungsu Park at the 4DBM Laboratory, Sungkyunkwan University, South Korea, where he was responsible for nucleic acid extraction, synthesis of biocompatible nanoparticles, and detection of airborne pathogens. These roles reflect his strong command over laboratory techniques such as qPCR, microbial culturing, and nanoparticle formulation. His involvement in multiple international collaborations and multi-disciplinary projects highlights his ability to adapt and contribute meaningfully to diverse research environments. His excellent work ethic, dedication to scientific rigor, and impressive publication record position him as a highly experienced and innovative researcher, making him a suitable candidate for recognition such as the Best Researcher Award.

Awards and Honors:

Shahab Uddin has received notable academic recognitions throughout his career. During his early education, he was awarded a fellowship by Islamia Model College, Timergara, which covered his tuition and admission fees. He received a laptop through the Prime Minister’s Laptop Scheme at the University of Peshawar, acknowledging his academic merit and performance. His consistent involvement in internationally recognized research projects and publications in top-tier journals has brought him visibility and respect within the scientific community. His work on microbial calcium carbonate precipitation, nanoparticle toxicity, and Parkinson’s disease treatments has earned accolades in both ecological and biomedical research circles. Beyond formal awards, his participation in collaborative research in China and South Korea is a testament to his growing international reputation. These honors reflect his commitment to scientific advancement and his ability to represent his country and field at a global level.

Research Focus:

Shahab Uddin’s research focuses on the interface of microbiology, nanotechnology, and biomedical science. His doctoral work involves using antibiotic-conjugated magnetic nanoparticles for rapid and precise preconcentration of periodontal bacteria, a novel approach for periodontitis diagnosis. He has also investigated the neuroinflammatory effects of fusion proteins, the role of nicotine in neuroprotection in Parkinson’s disease, and microbial-induced calcium carbonate precipitation for environmental applications. Shahab’s interests include mechanobiology, microbial genetics, and pathogen detection using qPCR. He is particularly passionate about translating microbial research into diagnostic and therapeutic applications. His collaborations with institutions in South Korea and China reflect a global perspective and adaptability in interdisciplinary research. With a portfolio that includes molecular biology, environmental microbiology, and advanced nanomaterials, Shahab’s work stands at the forefront of modern microbiological science. His research bridges basic science and applied solutions, aiming to contribute to global health, sustainable environments, and innovative diagnostics.

Publications Top Notes: 

  1. A comparative study on HSA and α-MSH fusion proteins for anti-neuroinflammatory effects – Neuropeptides

  2. Rigid linker peptides enhance stability and anti-inflammatory efficacy of HSA-α-MSH fusions – Biotechnology Journal

  3. Autophagy and UPS pathway in nicotine-induced protection for Parkinson’s disease – Experimental Brain Research

  4. Nicotine-mediated therapy in transgenic C. elegans model for Parkinson’s – Frontiers in Aging Neuroscience

  5. Microbially induced calcium carbonate precipitation to improve soil mechanics – Ecological Engineering

  6. Psychrotolerant Serratia marcescens HI6 characterization from glacier – Applied Ecology & Environmental Research

  7. Retrospective study on tuberculosis incidence in Dir Lower, Pakistan – Hospital Pharmacy

  8. Mechanobiological analysis of nanoparticle toxicity – Nanomaterials

  9. Microfabricated devices to study tensile stress on cells and tissues – BioChip Journal

  10. Incidence of HBV, HCV, HIV among blood donors in Peshawar – Population

Conclusion:

In conclusion, Shahab Uddin is an outstanding and promising researcher with a broad and impactful academic portfolio. His contributions span critical scientific areas including microbial pathogenesis, nanotechnology-enabled diagnostics, and neurodegenerative disease models. His dedication, innovation, and consistency in research make him highly deserving of recognition through the Best Researcher Award. While there is scope for leadership expansion and broader outreach, his current achievements—especially his multi-disciplinary publications and international collaborations—are commendable and reflect a researcher who is not only productive but also forward-thinking. Granting him this award would not only honor his contributions but also inspire continued scientific excellence and innovation in microbiology and beyond.

Yang Liu | Cell Migration Studies | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yang Liu | Cell Migration Studies | Best Researcher Award

Prof. Dr. Yang Liu, Taiyuan University of Technology Institute of Biomedical Engineering CHINA, China

Dr. Yang Liu is an Associate Professor at the Institute of Biomedical Engineering, Taiyuan University of Technology, China. Since joining in 2013, Dr. Liu has focused on biomechanics, particularly the mechanical mechanisms involved in skin tissue damage and healing processes during traumatic events like burns and radiotherapy. Her interdisciplinary work bridges molecular, cellular, and tissue-level studies to better understand the interplay between mechanical factors and skin regeneration. Her research also extends into the development and structural optimization of biomedical materials such as tissue-engineered skins and advanced dressings. Dr. Liu has led several research and teaching reform projects, obtained a patent transformation, and contributed to national and provincial-level scientific investigations. Her innovative work in tissue engineering and skin trauma treatment continues to contribute significantly to biomedical science and material engineering.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Specialized Expertise
    Dr. Liu focuses on biomechanics in disease development, particularly related to cutaneous trauma (e.g., burns, radiotherapy), a niche but critical area in biomedical engineering.

  2. Material Innovation
    Her work in developing tissue-engineered skin and antibacterial dressings demonstrates applied innovation with potential clinical relevance.

  3. Project Leadership
    Successfully led and participated in multiple competitive research projects funded by national and provincial bodies, indicating trust in her scientific vision and capabilities.

  4. Research Productivity
    Though early in recognition, Dr. Liu has already co-authored several peer-reviewed journal articles in reputable publications like Scientific Reports and Placenta, which reflect growing academic contribution.

  5. Translational Research
    Her involvement in a patent achievement transformation shows a commitment to moving research beyond the lab into real-world applications.

🔧 Areas for Improvement:

  1. Citation Impact and Indexing
    The provided articles currently have 0 citations, and there is no citation index or h-index reported. Increasing publication visibility and citation impact should be a future focus.

  2. Global Recognition and Collaboration
    There is no mention of international collaboration, editorial roles, or professional memberships, which would enhance credibility and reach.

  3. Documented Industry Linkages
    Despite some project engagement with enterprises, more evidence of sustained industry partnerships or commercialization success would strengthen the application.

  4. Books, Patents, and Conferences
    Absence of published books, patents in process, or keynote roles in international conferences limits the academic portfolio breadth.

🎓 Education:

Although specific degree details are not listed, Dr. Yang Liu has built a strong academic foundation that supports her expertise in biomedical engineering and biomechanics. Her academic journey is closely aligned with her professional role at Taiyuan University of Technology, which is known for its technical research capabilities. Dr. Liu’s knowledge spans skin tissue biology, mechanical trauma, and biomedical materials science, indicating a background that likely includes degrees in biomedical engineering, bioengineering, or a related field. Her educational experience has equipped her with the skills necessary to conduct high-level research in skin regeneration, materials science, and tissue biomechanics. Additionally, her active participation in national scientific projects and her leadership in academic innovation at the university level point to rigorous formal training and ongoing academic development.

🧪 Experience:

Dr. Yang Liu has over a decade of professional experience in biomedical research since joining the Taiyuan University of Technology in 2013. Her work has revolved around exploring the mechanical and biological factors involved in traumatic skin injury and healing. She has successfully led and contributed to multiple projects, including those funded by the National Natural Science Foundation of China and enterprise collaborations. In addition to her scientific contributions, she has also directed teaching reform projects and a patent transformation, highlighting her dual commitment to both research and education. Her experience includes a strong focus on interdisciplinary collaboration across biology, materials science, and mechanical engineering. This breadth of experience has allowed her to develop innovative biomedical materials, such as tissue-engineered skin and functional skin dressings, aimed at improving clinical treatment outcomes for burn injuries and other trauma-related skin conditions.

🔬 Research Focus:

Dr. Yang Liu’s research centers on the biomechanics of skin tissue damage and healing, with an emphasis on cutaneous trauma from burns and radiotherapy. Her work investigates how mechanical forces impact skin at multiple biological levels—molecular, cellular, tissue, and animal models. A major portion of her research explores biomedical material innovation, particularly tissue-engineered skin, skin dressings, and antibacterial materials. She is particularly focused on understanding how structural and mechanical properties of these materials can improve therapeutic outcomes. Dr. Liu also studies oxidative stress, cell migration, and protein responses under mechanical pressure, making her work crucial to trauma therapy and regenerative medicine. With a patent transformation and multiple research projects to her credit, her research is positioned at the intersection of engineering innovation and clinical application, aiming to reduce complications in skin trauma treatment and enhance recovery efficiency through scientifically engineered materials.

📚 Publications Top Notes:

  1. 🧴🧬 Preparation and characterization of nano-silver/graphene oxide antibacterial skin dressing – Scientific Reports, 2025

  2. 🔬⛽ Experimental study on liquid products and pore structure characteristics of anthracite saturated by supercritical CO₂ – Gas Science and Engineering, 2025

  3. 🧠💥 The regulatory role of the nuclear scaffold protein Emerin on the migration of amniotic epithelial cells and oxidative stress in a pressure environment – Placenta, 2025

  4. 🛠️🔥 Annealing Response of Cold-rolled Ti₂AlNb Based Alloy Foil in Different Phase Regions – Tezhong Zhuzao Ji Youse Hejin (Special Casting and Nonferrous Alloys), 2025

📝 Conclusion:

Dr. Yang Liu shows significant promise as a biomedical researcher, with a clear, focused research trajectory, practical outputs (materials for skin regeneration), and consistent project engagement at institutional and national levels. While her global visibility and citation metrics are currently limited, her research has high translational potential in trauma medicine and biomedical materials, making her a strong emerging contender for the Best Researcher Award—especially under a category recognizing early- to mid-career researchers with impactful applied science work.

Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Balbino Alarcón , Consejo Superior de Investigaciones Científicas , Spain

Balbino Alarcón is a leading Spanish immunologist renowned for his contributions to T cell biology and immune signaling. Currently serving as Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), he has been affiliated with the Centro de Biología Molecular Severo Ochoa since 2002. His research has played a pivotal role in uncovering mechanisms of T cell receptor (TCR) signaling and immune system regulation. Dr. Alarcón holds a PhD in Biology from the Universidad Autónoma de Madrid, where he began shaping his scientific journey in the early 1980s. Over the decades, he has authored numerous impactful publications, many in top-tier journals, and holds several patents licensed to biotech companies. His work bridges fundamental immunology with translational applications in autoimmunity and cancer. With a keen focus on molecular signaling, his research continues to influence both basic science and therapeutic innovation in immunology.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Outstanding Research Contributions:
    Dr. Alarcón has made seminal contributions to immunology, especially in T cell receptor (TCR) signaling, immune synapse formation, and immune cell communication. His work has appeared in top-tier journals like Cell, Immunity, Nature Communications, and Journal of Experimental Medicine.

  2. Impactful Publications & Citations:
    His research includes several highly cited papers (e.g., >500 citations), underlining the influence of his work on the broader scientific community.

  3. Translational Achievements:
    He holds multiple patents on immunomodulatory molecules (e.g., AX-024), which were licensed to biotech company Artax Biopharma, bridging basic science and clinical application.

  4. SARS-CoV-2 Research Leadership:
    He actively contributed to COVID-19 immunity research, developing flow cytometry-based antibody detection techniques and tracking longitudinal immune responses to infection and vaccination.

  5. Longevity and Commitment:
    Over 40 years of consistent research activity, with continuous affiliation to one of Spain’s most prestigious scientific institutions, CSIC.

  6. International Collaboration:
    He co-authored papers with leaders in immunology, showing global recognition and collaboration.

🛠️ Areas for Improvement:

  • Public Engagement & Visibility:
    Despite scientific acclaim, more visibility in public science communication, conference keynote roles, or leadership in global immunology consortia would further support his candidacy.

  • Mentorship Highlighting:
    While his academic stature suggests mentorship, documentation or awards for training young scientists could enhance his profile for broader awards recognizing holistic impact.

  • Innovation Metrics:
    Increased emphasis on clinical translation or successful product development from his patents could strengthen claims to innovation-driven recognitions.

🎓 Education:

Dr. Balbino Alarcón completed his undergraduate degree (Licenciado en Biología) in 1982 and his PhD in Biology with a specialization in Biochemistry in 1985, both from the Universidad Autónoma de Madrid, Spain. During his academic formation, he developed a deep interest in immunological signaling, particularly in how T cells communicate with their environment. His early education laid the foundation for a distinguished research career that has spanned more than three decades. His doctoral studies were focused on cellular and molecular immunology, equipping him with the tools to explore intricate signaling pathways. This robust educational background positioned him for leadership roles in immunological research, both nationally and internationally. Through rigorous academic training and continuous research contributions, Dr. Alarcón has become a key figure in advancing our understanding of T cell function and immune regulation.

👨‍🔬 Experience:

Dr. Balbino Alarcón has over 40 years of experience in immunological research, with a primary focus on T cell receptor (TCR) signaling and lymphocyte activation. Since July 27, 2002, he has held the position of Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), working at the Centro de Biología Molecular Severo Ochoa in Madrid, Spain. His academic and research career began with groundbreaking studies in T cell immunobiology, leading to discoveries such as the role of conformational changes in TCR activation. Dr. Alarcón has also been deeply involved in translational research, co-developing immunomodulatory drugs and securing patents that were licensed to Artax Biopharma. He regularly collaborates with leading immunologists and institutions worldwide, contributing to high-impact publications and international scientific reviews. His expertise and sustained contributions have made him a mentor and authority in molecular immunology and T cell biology.

🏅 Awards and Honors:

Dr. Balbino Alarcón’s distinguished career is highlighted by several prestigious awards and intellectual property recognitions. He co-developed two patented immunosuppressive strategies based on TCR signaling inhibition: one disrupting the TCR-Nck interaction and another involving chromene derivatives. Both patents were licensed to Artax Biopharma, showcasing the real-world therapeutic relevance of his research. He has authored highly cited publications, including foundational work published in Cell, Immunity, and Annual Review of Immunology, with citations in the hundreds. These contributions have not only advanced the field of immunology but also positioned Dr. Alarcón as a thought leader in immune signal transduction. He has been recognized nationally and internationally for his scientific achievements, serving as an editorial contributor and co-author of influential immunological reviews. His work continues to shape both academic and pharmaceutical research, making him a strong candidate for Best Researcher Awards.

🔬 Research Focus:

Dr. Alarcón’s research centers on the molecular mechanisms governing T cell receptor (TCR) activation and signal transduction. His work dissects how T cells recognize antigens and how intracellular signaling cascades translate these interactions into immune responses. A significant aspect of his research has involved understanding the conformational dynamics of the TCR/CD3 complex and how this affects T cell sensitivity and activation thresholds. He also explores the role of RRas2 in T and B cell function, including its relevance in lymphomagenesis and autoimmunity. Recently, he has contributed to understanding immune responses to SARS-CoV-2 and methods to detect neutralizing antibodies. His interdisciplinary approach integrates cell biology, molecular immunology, and translational research, linking fundamental science to clinical applications such as vaccine development and immunotherapy. By targeting TCR-associated pathways, Dr. Alarcón’s research opens new avenues in the treatment of immune-related diseases and cancer.

📚 Publications Top Notes:

  1. 🧫 RRas2 is required for germinal center formation to aid B cells during energetically demanding processes (Sci Signal, 2018)

  2. 🧪 A window of opportunity for cooperativity in the T Cell Receptor (Nat Commun, 2018)

  3. 🧬 Antigen phagocytosis by B cells is required for a potent humoral response (EMBO Rep, 2018)

  4. ⚙️ RRAS2 shapes the TCR repertoire by setting the threshold for negative selection (J Exp Med, 2019)

  5. 💊 Small molecule AX-024 targets T cell receptor signaling by disrupting CD3ε-Nck interaction (J Biol Chem, 2020)

  6. 🧪 Flow cytometry multiplexed method for the detection of Neutralizing human antibodies to SARS-CoV-2 (EMBO Mol Med, 2021)

  7. 🧬 Antigen presentation between T-cells drives Th17 polarization under limiting antigen (Cell Rep, 2021)

  8. 🧫 Detection of sustained humoral immune response (IgG + IgA) in SARS-CoV-2 infection (Sci Rep, 2021)

  9. 🧠 SFRP1 modulates astrocyte-to-microglia crosstalk in neuroinflammation (EMBO Rep, 2021)

  10. 💉 Longitudinal dynamics of SARS-CoV-2-specific immunity after infection or vaccination (PLoS Pathog, 2021)

🧾 Conclusion:

Dr. Balbino Alarcón is a highly deserving candidate for the Best Researcher Award. His pioneering studies in T cell signaling, impactful biomedical patents, and active role in immune response to infectious diseases demonstrate excellence in both basic and translational immunology. With decades of productive research, interdisciplinary collaboration, and consistent scientific leadership, he embodies the qualities celebrated by such an award.

Zhirong Tan | Gene Regulation Epigenetics | Best Researcher Award

Published on by Cell Biologist

Prof. Zhirong Tan | Gene Regulation Epigenetics | Best Researcher Award

Prof. Zhirong Tan  , Xiangya Hospital, Central South University , China

Professor Zhirong Tan is a leading Chinese expert in pharmacogenomics and clinical pharmacology. Currently a professor at Xiangya Hospital, Central South University, he also serves as the Director of the Pharmacogenetics and Pharmacokinetics Research Laboratory and Deputy Director of the Drug Analysis Center. He has been instrumental in over 300 clinical trials, pushing forward the frontiers of precision medicine, especially in colorectal cancer and Alzheimer’s disease. With over 20 SCI papers, multiple patents, and co-authorship of four books, he’s widely recognized for his work in pharmacokinetics and biomarker discovery. A national GCP and GMP inspector, Prof. Tan actively contributes to pharmaceutical regulation and innovation in China. His academic and industry partnerships reflect a robust foundation in translational research and real-world drug development.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Prof. Zhirong Tan has made outstanding contributions to clinical pharmacology, pharmacogenetics, and metabolomics over two decades. His research has provided critical insights into drug metabolism, biomarker discovery, and precision medicine, especially in colorectal cancer and Alzheimer’s disease.

  2. Prolific Publication Record
    With over 22 SCI-indexed publications (first or corresponding author) and 6 CSCD papers, Prof. Tan’s research has achieved over 3550 citations and an H-index of 33 on Web of Science—evidence of the high impact and recognition of his work.

  3. Strong National & Industry Collaborations
    He has participated in or led 300+ clinical trials and secured 5 “Million+” industry-funded projects, reflecting strong ties with both academia and industry. His leadership in national-level projects, such as the “Major New Drug Development” program, showcases his influence in China’s healthcare innovation.

  4. Intellectual Property and Innovation
    With 3 granted patents and 3 under review, Prof. Tan’s ability to translate research into practical applications is evident. His individualized esomeprazole dosing regimen highlights innovation at the clinical level.

  5. Regulatory & Policy Contributions
    As a national GCP/GMP inspector, he plays a pivotal role in drug trial ethics and compliance in China. He also holds leadership roles in pharmacogenomics committees, further demonstrating his commitment to public health advancement.

  6. Academic Mentorship and Editorial Work
    In addition to research, Prof. Tan contributes as a journal reviewer, co-author of four textbooks, and mentor to the next generation of scientists, reinforcing his role as a thought leader in the field.

🔍 Areas for Improvement:

  1. International Visibility
    While Prof. Tan’s national presence is remarkable, further international collaborations, invited keynotes at global conferences, or leading roles in global consortia could enhance his visibility and expand the influence of his work.

  2. Broader Publication Range
    Publishing more frequently in top-tier international journals (e.g., Nature, The Lancet, NEJM) would increase the global academic reach of his findings.

  3. Open Science & Data Sharing
    As the field moves toward transparency, incorporating open-access publications and shared data repositories could boost both reproducibility and citations.

🎓 Education:

Professor Zhirong Tan obtained his Ph.D. from Central South University, a premier Chinese institution, where he laid the groundwork for his expertise in clinical pharmacology and pharmacogenomics. He later pursued postdoctoral research at the School of Pharmacy, University of Maryland, Baltimore, one of the top pharmaceutical research institutions in the United States. This international experience enabled him to gain a global perspective in drug metabolism, biomarker identification, and translational pharmacology. His academic training focused on cutting-edge methodologies such as metabolomics, pharmacokinetics, and precision medicine. Through continuous education and research, he has built a reputation as a highly skilled pharmacologist whose work bridges basic research and clinical applications.

💼 Experience:

With a research career spanning over two decades since 1998, Professor Zhirong Tan has led and participated in numerous national-level and provincial-level projects, including China’s National Science and Technology Major Projects. He currently holds multiple leadership positions at Xiangya Hospital, Central South University. Over the years, he has completed major research grants from NSFC, the Hunan Province, and the Ministry of Science and Technology. As a GCP and GMP inspector, Prof. Tan has overseen more than 300 clinical trials, ensuring drug development meets regulatory and ethical standards. His experience also extends to industry collaboration, with successful execution of 5 “Million+” funded projects and influential roles in pharma-academic alliances. A frequent peer reviewer and contributor to international journals, his work influences both the scientific community and regulatory frameworks.

🔬 Research Focus:

Professor Tan’s primary research focus lies in clinical pharmacology, pharmacogenomics, and metabolomics, particularly for colorectal cancer and Alzheimer’s disease. His work aims to identify and validate biomarkers for disease diagnosis, drug efficacy, and toxicity prediction. A major contributor to China’s “Major New Drug Development” initiative, he has developed personalized esomeprazole dosing regimens by studying genetic polymorphisms, SNPs, and microRNA interactions. His research also explores the pathogenesis of Alzheimer’s disease using metabolomic profiling, offering insights into early detection and potential therapeutics. He applies advanced bioanalytical methods to understand inter-individual variability in drug metabolism and therapeutic response. His projects have real-world clinical implications, transforming how drugs are prescribed, regulated, and monitored. Through his pioneering work, Prof. Tan contributes significantly to the evolution of precision medicine in China.

📚 Publication Top Notes:

  1. 📊 Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

  2. ❤️ Gly389Arg polymorphism of β1‐adrenergic receptor and cardiovascular response to metoprolol

  3. 💊 CYP2C19 ultra-rapid metabolizer genotype affects voriconazole pharmacokinetics

  4. 🧬 HLA‐B35:01 allele as biomarker for Polygonum multiflorum–induced liver injury*

  5. 🌿 Repeated berberine administration inhibits cytochromes P450 in humans

  6. 💉 Effect of SLCO1B1 polymorphism on pharmacokinetics of nateglinide

  7. 🧪 Assessment of cytochrome P450 activity by five‐drug cocktail approach

  8. ☕ Plasma caffeine metabolite ratio linked to CYP1A2 polymorphisms

  9. 🔬 Inducibility of CYP1A2 by omeprazole associated with genetic polymorphism

  10. 🧫 Ile118Val polymorphism of CYP3A4 affects simvastatin lipid-lowering efficacy

📝 Conclusion:

Professor Zhirong Tan is a highly deserving candidate for the Best Researcher Award. His record of scientific excellence, clinical innovation, and regulatory leadership clearly positions him as a key contributor to modern pharmacology. His integrated approach—spanning basic science, clinical trials, and health policy—has had a measurable impact on patient care and drug development in China.

While there is room to further expand his global footprint, his accomplishments to date already demonstrate the caliber, commitment, and consistency expected of a world-class researcher.